- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
190 CHAPTER 6 Urological neoplasia
Prostate cancer: epidemiology and etiology
Hormonal influence
Growth of prostate cancer (PC), like benign prostatic epithelium, is under the influence of testosterone and its potent metabolite, dihydrotestosterone. Removal of these androgens by castration largely results in programmed cell death (apoptosis) and involution of the prostate. PC is not seen in eunuchs or people with congenital deficiency of 5-A-reductase (5AR), which converts testosterone to dihydrotestosterone (DHT).
Estrogens, including phytoestrogens found in foodstuffs used in Asian and Oriental cuisine, have a similar negative growth effect on PC. This is one explanation why individuals in this part of the world are less likely to develop clinical disease and have lower death rates from prostate cancer.
Other proposed dietary inhibitors of PC growth include vitamins E and D, and the antioxidants lycopene (present in cooked tomatoes) and the trace element selenium (see also p. 244). A very large U.S. trial (SELECT Trial) failed to demonstrate that formulations of vitamin E and selenium, used alone or in combination, could reduce the risk of PC.
Genetics
The multifocal and heterogeneous nature of PC makes clinical genetic studies difficult, as this cancer exhibits numerous genetic abnormalities, increasing with more advanced stage and grade.
Identified genetic changes include inactivation of tumor suppressor genes PTEN (chromosome 10q) and p53 (chromosome 17p), activation of c-myc and bcl-2 proto-oncogenes, and PC susceptibility genes such as ELAC2/HPC2, SR-A/MSR1, CHEK2, BRCA2, and others. Shortened CAG repeat length in the androgen receptor gene is associated with an increased risk of the disease.
Risk factors
Age
This is an important risk factor for development of histological PC. Less than 10% of cases are diagnosed in men <54 years of age, with 64% of cases diagnosed between 55 and 74 years of age. Autopsy prevalence of PC rises from 31% for men in their 30’s to 83% in their 80’s.
This rise is paralleled several years earlier by a premalignant lesion— high-grade prostatic intraepithelial neoplasia (HGPIN). However, most prostate cancer does not achieve a clinically recognizable and aggressive state.
Geographic variation
The disease appears to be more common in Western nations, particularly Scandinavian countries and the United States. The clinical diagnosis of the disease is less common in Asia and the Far East, but immigrants to the United States from Asia and Japan have a 20-fold increased risk. This suggests an environmental etiology, such as the Western diet (higher levels of meat, dairy, and saturated fat), may be important.
PROSTATE CANCER: EPIDEMIOLOGY AND ETIOLOGY 191
Race
Black men are at greater risk than Caucasians; Asians and Oriental races have a low risk of prostate cancer unless they migrate to the West. The world’s highest incidence is among U.S. and Jamaican Blacks, although there are few reliable data available regarding African and European Blacks.
Family history
From 5% to 10% of prostate cancer cases are thought to be inherited. Hereditary PC tends to occur in younger (<55 years) men who have a family history of multiple relatives afflicted; genetic abnormalities on chromosomes 1q, 8p, Xp and mutations of the BRCA2 gene are reported.
The risk of a man developing PC is doubled if there is one affected first-degree relative and can be further increased if there are two. A familial association between breast cancer and prostate cancer has also been suggested.
HPC-1 gene on chromosome 1 is strongly associated with familial PC; HPC-1 mutation results in defective RNase L and accumulation of genetic defects, and eventually prostate cancer.
Familial PC tends to follow a similar clinical course to sporadic PC.
Other factors
Some controversy surrounds the possible increased risk of developing PC conferred by sexual overactivity, viral infections, and vasectomy. The balance of data and opinion currently go against these putative risk factors. Exposure to cadmium has been suggested to raise the risk of PC, but convincing contemporary data are lacking.
192 CHAPTER 6 Urological neoplasia
Prostate cancer: incidence, prevalence, and mortality
Incidence
The widespread use of prostatic-specific antigen (PSA)-based screening led to a sharp increase in the incidence of prostate cancer that peaked the early 1990s in the United States.
In 2010 men were diagnosed with prostate cancer in the United States. This exceeds the number of men diagnosed with lung cancer (116,759), placing prostate cancer as the most commonly diagnosed male cancer (excluding basal and squamous cell skin cancers). It accounts for about 33% of all male cancers diagnosed.
Prevalence
Currently, it is estimated that a man in the United States has a 1 in 6 (16.6%) lifetime risk of being diagnosed with prostate cancer as a result of clinical symptoms, signs, or PSA testing. However, the true prevalence of the disease is hinted at by postmortem studies carried out on men who have died of other causes.
There is a significant number of men with so-called autopsy cancers. This concept of latent prostate cancer—a biologically nonaggressive and slow-growing form of the disease, may be unnecessarily detected by aggressive PSA screening (p. 216).
Mortality
It is estimated that prostate cancer accounts for 9% of male cancer deaths. Mortality increased slowly in the UK and United States during the 1970s and 1980s, peaking in the 1990s and slowly decreasing thereafter. Mortality has declined 4% per year between 1999 and 2003.
In 2009, 27,360 deaths were attributed to prostate cancer in the United States, the second-most common form of male cancer death. This compares with 25,240 deaths due to colorectal cancer and 88,900 due to lung cancer.
The explanation for the reduced prostate cancer mortality is highly controversial. The potential reasons for this decline include improved diagnosis and treatment of localized disease, the early use of hormonal therapy, and PSA-based screening.
The concept of screening for prostate cancer detecting earlier stages and possibly more curable disease remains highly controversial, with various studies supporting and refuting the effectiveness of screening based on PSA testing and rectal examination (see p. 194).
PROSTATE CANCER PATHOLOGY: PREMALIGNANT LESIONS 193
Prostate cancer pathology: premalignant lesions
Two histological lesions are currently regarded as either premalignant or “perimalignant” (related to the presence of cancer)—prostatic intraepithelial neoplasia (PIN) and atypical small acinar proliferation (ASAP).
Prostatic intraepithelial neoplasia
PIN consists of architecturally benign prostatic acini and ducts lined by cytologically atypical cells and confined within the epithelium. The basal cell layer is present, although the basement membrane may be fragmented.
PIN was formerly known as ductal dysplasia or reported by pathologists as “suspicious for cancer.” PIN was classified into low-grade (mild) and high-grade (moderate to severe) forms, based on the presence of prominent nucleoli. Subsequently, pathologists have agreed to report only highgrade PIN, since low-grade PIN has no prognostic value.
High-grade PIN is believed by many to be to be a precursor to intermediateor high-grade prostate cancer and its finding in sextant peripheral zone prostate biopsies carries a 30–40% prediction of prostate cancer at subsequent biopsy. However, with the widespread use of more extensive biopsy protocols, the significance of isolated high-grade PIN has become less clear.
High-grade PIN is reported in 5–10% of prostate needle biopsies. It does not appear to affect the serum PSA value. The site of the PIN is not indicative of the site of subsequently diagnosed cancer, nor is PIN always present in a prostate containing cancer.
Most authors recommended that repeat systematic biopsies be performed in 3–6 months if multifocal high-grade PIN is reported on initial needle biopsy or transurethral resection of the prostate (TURP). Studies also suggest that a repeat biopsy may be unnecessary in the setting of isolated high-grade PIN without other clinical indicators of cancer.
Atypical small acinar proliferation
ASAP is a histological finding suggesting that a focus of atypical glands is suspicious for cancer. ASAP and HGPIN are distinct entities and the two should not be used interchangeably. The ASAP acini are small, lined with cytologically abnormal epithelial cells. The columnar cells have prominent nuclei containing nucleoli, while the basal layer may be focally absent. The basement membrane is intact.
Prostate cancer has been identified in specimens from subsequent biopsies in up to 60% of cases of ASAP, indicating that this finding is a significant predictor of cancer. Identification of ASAP (with or without high-grade PIN) warrants repeat biopsy for concurrent or subsequent invasive prostate carcinoma.
194 CHAPTER 6 Urological neoplasia
Prostatic-specific antigen (PSA) and prostate cancer screening
Screening men aged 50–70 years with PSA and digital rectal examination (DRE), and subsequent early detection and treatment, may reduce the significant mortality and morbidity caused by prostate cancer. Supporters of screening say these acceptable and relatively inexpensive tests will detect clinically significant disease before it leaves the prostate.
The lead time, estimated at 6–12 years, between the screened diagnosis and the clinical diagnosis should enable more organ-confined cancers to be diagnosed and cured. However, because of the low specificity of PSA (40%) and the high prevalence of latent or autopsy prostate cancer, opponents argue that many men would suffer unnecessary anxiety, biopsies, overdiagnosis (25–50%), and overtreatment.
Two long-awaited screening studies were reported in 2009 with conflicting data. The U.S. PLCO (Prostate Lung Colorectal and Ovarian) screening study did not demonstrate a reduction in prostate cancer mortality.1 However, the study was considered “contaminated” by many, as a large number of men were prescreened and the control group was contaminated by this screening outside of the study. The ERSPC (European Randomized Study of Screening for Prostate Cancer) trial demonstrated a 20% reduction in mortality and a 25% reduction in metastatic disease due to screening.2
Decisions regarding early detection of prostate cancer should be individualized, and benefits and consequences should be discussed with the patient before PSA testing occurs. Not all men are appropriate candidates for screening efforts for this disease. Ideally, physicians should consider a number of factors, including patient age and comorbidity, as well as preferences for the relevant potential outcomes.
The practice of screening in men with less than a 10-year life expectancy (due to age or comorbidity) should generally be discouraged.4 Informed consent prior to PSA testing has been recommended by some groups. The American Urological Association (AUA) 2009 guideline recommends that early detection and risk assessment of prostate cancer be offered to asymptomatic men 40 years of age or older who wish to be screened and have an estimated life expectancy of more than 10 years.
If the patient and clinician are interested in the best objective data on determining the risk of biopsy-detectable prostate cancer, the National Cancer Institute (NCI) has published a risk calculator3 based on the Prostate Cancer Prevention Trial.
1 Andriole G, et al. (2009). Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319.
2 Schröder F, et al. (2009). Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328.
3 Available at: http://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp. (Accessed July 2009). Race, age, PSA level, family history, prior prostate biopsy, and the use of finasteride are factors that are entered into the system.
4 Smith, RA, et al (2010). Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening CA Cancer J Clin 60:70–98.